Patent details

EP1877070 Title: THERAPEUTIC USE OF TGF-BETA2 ANTISENSE OLIGONUCLEOTIDES

Basic Information

Publication number:
EP1877070
PCT Application Number:
PCT/EP/2006/062067
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP067550244
PCT Publication Number:
WO/2006/117400
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
THERAPEUTIC USE OF TGF-BETA2 ANTISENSE OLIGONUCLEOTIDES
French Title of Invention:
UTILISATION THERAPEUTIQUE D'OLIGONUCLEOTIDES ANTISENS A TGF-BETA2
German Title of Invention:
VERWENDUNG VON TGF-BETA2 ANTISENSE OLIGONUKLEOTIDEN
SPC Number:

Dates

Filing date:
04/05/2006
Grant date:
31/12/2008
EP Publication Date:
31/12/2008
PCT Publication Date:
09/11/2006
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
16/01/2008
EP B1 Publication Date:
31/12/2008
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
04/05/2018
Expiration date:
04/05/2026
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
04/05/2006
 
 

Name:
Antisense Pharma GmbH
Address:
Josef Engert Strasse 9, 93053 Regensburg, Germany (DE)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
21/01/2009
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Inventor

1

Name:
SCHLINGENSIEPEN Reimar
Address:
Germany (DE)

2

Name:
SCHLINGENSIEPEN Karl-Hermann
Address:
Germany (DE)

Priority

1

Priority Number:
05009802
Priority Date:
05/05/2005
Priority Country:
European Patent Office (EPO) (EP)

2

Priority Number:
680493 P
Priority Date:
13/05/2005
Priority Country:
United States (US)

Classification

Main IPC Class:
A61K 31/7125;

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
29/05/2017
Last Annual Fee Paid Number:
12
Last Annual Fee Paid Amount:
165 Euro
Payer:
OFFICE FREYLINGER S.A.
Filing date Document type Number of pages
30/09/2018 Outgoing Correspondence 1